Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Prabhani Atukorale · UNIVERSITY OF MASSACHUSETTS AMHERST · 2023 · $237,749 — PROJECT SUMMARY This proposal seeks to develop a targeted tri-agonist “super adjuvant” nanoparticle platform for in situ cancer vaccination. Vaccines consist of 2 components: a tumor-specific antigen that is recognized by CD8+ cytotoxic T cells (CTLs) and an adjuvant that provides the necessary cost…
Kiran Musunuru · CHILDREN'S HOSP OF PHILADELPHIA · 2023 · $6,415,703 — PROJECT SUMMARY The potential for the development of novel therapeutic modalities has energized the genome editing field since it first emerged in the 1990s and especially since the demonstration of programmable genome editing with CRISPR-Cas9 by multiple groups in 2012. There has been substantial p…
William H. Gmeiner · DEEP CREEK PHARMA, LLC · 2023 · $964,465 — PROJECT SUMMARY Decades of modulating the anti-cancer activity of fluoropyrimidine drugs (FPs) thru schedule optimization, biochemical modulation, and drug combinations have provided a significant, but limited, survival advantage for treating colorectal cancer (CRC) patients with locally advanced or…
Bulent Ozpolat · METHODIST HOSPITAL RESEARCH INSTITUTE · 2023 · $362,163 — Project Summary Triple negative breast cancer (TNBC) has the worst prognosis and survival in all breast cancer subtypes with currently available standard therapies, representing an unmet therapeutic challenge. Significant heterogeneity (with six genetically defined subgroups) and a lack of FDA-appro…
Rohan Palanki · UNIVERSITY OF PENNSYLVANIA · 2023 · $52,694 — PROJECT SUMMARY Congenital lung diseases, such as inherited surfactant protein syndromes, cystic fibrosis, and alpha-1 antitrypsin deficiency, are a significant source of pediatric morbidity and mortality. Treatment options for neonatal patients with lung disorders that present with respiratory fail…
William H. Gmeiner · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 2023 · $592,748 — PROJECT SUMMARY Metastatic colorectal cancer (mCRC) remains highly lethal despite decades of optimizing 5-fluorouracil (5-FU)- based combination chemotherapy regimens that are central to treatment. The causes of treatment failure with 5-FU-based regimens include decreased metabolism to FdUMP, the pr…
Jianxin You · UNIVERSITY OF PENNSYLVANIA · 2023 · $371,719 — Project Summary Merkel cell polyomavirus (MCPyV) is a ubiquitous skin infection that can cause Merkel cell carcinoma (MCC), a highly aggressive form of skin cancer. Immune suppression is one of the most important risk factors for developing MCPyV-associated MCC. MCPyV has a far greater chance to ind…
Ram I. Mahato · UNIVERSITY OF NEBRASKA MEDICAL CENTER · 2023 · $420,765 — PROJECT SUMMARY Liver injury from alcohol abuse, and obesity can lead to liver inflammation, steatosis, and fibrosis. Liver cell damage results in the release of inflammatory cytokines from hepatocytes and Kupffer cells (KCs), which cause the activation of hepatic stellate cells (HSCs). If unresolv…
Rebecca Sara Cook · VANDERBILT UNIVERSITY · 2023 · $555,637 — Cancer nano-formulations for delivery of small molecule drugs are limited by the ability to target only ~10% of the genome. RNAi molecules can, in theory, be designed against any gene of interest, but siRNA use in clinical oncology faces delivery barriers such as nuclease degradation, rapid renal cl…
Peng Zhang · NORTHWESTERN UNIVERSITY AT CHICAGO · 2023 · $358,680 — PROJECT SUMMARY/ABSTRACT Radiation therapy (RT) is a key component of standard of care treatments for glioblastoma (GBM), the most common and deadly primary brain malignancy in adults. Beyond the direct cytotoxic effect on tumor itself, RT- elicited anti-tumor immune responses have recently been app…
Jacob Daggett Ramsey · UNIV OF NORTH CAROLINA CHAPEL HILL · 2023 · $39,214 — Abstract/Project Summary Polymeric micelles are powerful drug delivery vehicles with a promising future. There are currently no US Food and Drug Administration approved polymeric micelle formulations, but some have been approved by the European Medicines Agency and other international regulatory bod…
ASMA NUSRAT · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2023 · $460,345 — Abstract The gastrointestinal epithelium plays a central role in maintaining and coordinating mucosal homeostasis and immunity. Intestinal epithelial barrier compromise in mucosal wounds is seen in many pathologic states that encompass inflammatory bowel diseases, ischemia, mechanical injury and sur…
Efstathios Karathanasis · CASE WESTERN RESERVE UNIVERSITY · 2023 · $578,041 — PROJECT SUMMARY First-line chemotherapy is the standard of care for patients with triple-negative breast cancer (TNBC). While short-term response is achievable, most patients succumb to recurrence due to metastasis. Micrometastasis encompasses a small population of dormant disseminated tumor cells (…
Daniel John Siegwart · UT SOUTHWESTERN MEDICAL CENTER · 2023 · $383,887 — Project Summary The programmable CRISPR/Cas gene editing system has great potential for cancer treatment due to the ability to precisely inactivate or repair cancer-related genes. However, delivery of CRISPR to solid tumors for efficient cancer therapy remains limited by the uniquely stiff and fibro…
THOMAS D. SCHMITTGEN · UNIVERSITY OF FLORIDA · 2023 · $178,234 — Project Summary Pancreatic ductal adenocarcinoma (PDAC) is currently the third most lethal cancer in the United States. It is currently the third leading of cancer-related deaths in the United States and by the end of this decade, pancreatic cancer is predicted to pass colorectal cancer, making it t…
Jonathan Henry Shannahan · PURDUE UNIVERSITY · 2023 · $337,723 — Project Summary / Abstract Individuals with metabolic syndrome (MetS) compose a significant and growing proportion of our U.S. and global population (> 25%). It has been established that the presence of chronic diseases, such as MetS, enhances and prolongs environmental exposure-induced inflammation…
David G. Keener · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2023 · $32,460 — PROJECT SUMMARY Infants with Rett syndrome (Rett) are born with loss-of-function mutations in the gene encoding MeCP2, a global regulator of gene expression. MeCP2 dysfunction in the brain severely affects neurons, leading to developmental deficits of varying severity that manifest after 6 months of…
NAGI G AYAD · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · 2023 · $1,320,578 — PROJECT SUMMARY/ABSTRACT Despite decades of intensive research, there are currently no disease-modifying therapies to treat spinal cord injury (SCI). One major reason for this dire unmet need is the spatiotemporal heterogeneity of the cells that comprise the injury site. Therapeutic molecules (e.g.,…
Virender Kumar · UNIVERSITY OF TOLEDO · 2023 · $390,185 — PROJECT SUMMARY Alcohol-associated liver disease (ALD) is a significant health problem caused by excessive alcohol consumption. ALD is generally discovered in association with fatty liver, steatosis, or fibrosis progression, leading to cirrhosis. Unfortunately, there is no approved drug for ALD, and…
FENG C LIN · CLEVELAND CLINIC LERNER COM-CWRU · 2023 · $402,500 — Abstract Autoimmune uveitis, a common cause of blindness, has an unknown etiology and no known cure. We have been studying experimental autoimmune uveitis (EAU) induced in mice deficient in various complement components, inhibitors, or receptors following active immunization with a retinal antigen …